US Stock MarketDetailed Quotes
QNCX Quince Therapeutics
- 1.900
- +0.310+19.50%
Close Nov 14 16:00 ET
83.60MMarket Cap-1532P/E (TTM)
1.950High1.560Low572.88KVolume1.560Open1.590Pre Close1.03MTurnover1.62%Turnover RatioLossP/E (Static)44.00MShares1.95052wk High1.86P/B67.12MFloat Cap0.51252wk Low--Dividend TTM35.33MShs Float121.980Historical High--Div YieldTTM24.53%Amplitude0.512Historical Low1.796Avg Price1Lot Size
Quince Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -128.35%-8.74M | -134.04%-8.35M | 58.46%-18.29M | -4.16%-6.08M | 28.06%-4.82M | 75.17%-3.83M | 77.82%-3.57M | 30.02%-44.04M | 59.53%-5.84M | 61.38%-6.7M |
| Net income from continuing operations | -467.52%-27.73M | 9.02%-11.15M | 39.25%-31.39M | -60.72%-8.89M | 32.45%-5.35M | 70.50%-4.89M | 43.38%-12.25M | 42.56%-51.66M | 76.35%-5.53M | 63.51%-7.92M |
| Operating gains losses | ---- | ---- | -143.62%-41K | -300.00%-34K | ---8K | ---2K | --3K | --94K | --17K | --0 |
| Depreciation and amortization | 4,300.00%44K | 135.29%40K | 57.84%322K | 623.81%304K | --0 | -98.81%1K | -55.26%17K | -40.70%204K | -50.00%42K | -54.02%40K |
| Other non cash items | --2.64M | 1,282.66%2.93M | 632.91%1.67M | 6,706.90%1.92M | --0 | --0 | ---248K | -257.29%-313K | ---29K | ---- |
| Change In working capital | -807.46%-1.42M | -150.16%-805K | 120.11%1.98M | 114.15%250K | 71.89%-79K | 105.13%201K | 141.55%1.61M | -130.67%-9.83M | -961.95%-1.77M | 92.17%-281K |
| -Change in prepaid assets | -223.04%-1.6M | -131.14%-440K | 64.57%4.25M | 972.83%1.97M | -168.58%-443K | -23.77%1.3M | 3,264.29%1.41M | 411.22%2.58M | 27.78%184K | -26.42%646K |
| -Change in payables and accrued expense | 134.28%436K | -235.86%-322K | 82.07%-2.26M | 22.69%-1.52M | 131.20%298K | 77.32%-1.27M | 105.82%237K | -284.59%-12.6M | -3,277.42%-1.97M | 78.39%-955K |
| -Change in other current assets | ---110K | ---8K | -104.64%-9K | -147.37%-9K | ---- | ---- | --0 | 225.16%194K | 2,000.00%19K | 158.33%28K |
| -Change in other working capital | -185.38%-146K | 22.22%-35K | ---- | ---- | --66K | --171K | ---45K | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -128.35%-8.74M | -134.04%-8.35M | 58.46%-18.29M | -4.16%-6.08M | 28.06%-4.82M | 75.17%-3.83M | 77.82%-3.57M | 30.02%-44.04M | 59.53%-5.84M | 61.38%-6.7M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 75.51%-4.98M | 60.90%8.91M | -131.99%-5.76M | -71.12%5.39M | 141.19%3.64M | -287.03%-20.32M | -58.70%5.54M | -69.46%18M | -10.77%18.67M | -1,252.22%-8.83M |
| Net PPE purchase and sale | ---39K | 71.32%-39K | -20.30%-160K | 22.97%-114K | 350.00%90K | --0 | -2,620.00%-136K | 26.11%-133K | -236.36%-148K | --20K |
| Net business purchase and sale | ---- | ---- | -119.98%-2.12M | ---2.12M | ---- | ---- | ---- | --10.59M | --0 | --0 |
| Net investment purchase and sale | 75.70%-4.94M | 60.28%8.95M | -134.42%-2.57M | -57.16%8.03M | 146.93%4.14M | -27.99%-20.32M | -58.37%5.59M | -87.36%7.47M | -10.59%18.74M | -1,250.26%-8.81M |
| Net other investing changes | ---- | ---- | -1,400.00%-910K | ---410K | ---590K | --0 | --90K | --70K | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 75.51%-4.98M | 60.90%8.91M | -131.99%-5.76M | -71.12%5.39M | 141.19%3.64M | -287.03%-20.32M | -58.70%5.54M | -69.46%18M | -10.77%18.67M | -1,252.22%-8.83M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 34.62%35K | 280.00%190K | -79.77%143K | 416.67%57K | 300.00%10K | -75.93%26K | -91.96%50K | -89.62%707K | -101.82%-18K | -100.11%-5K |
| Net issuance payments of debt | --0 | --0 | 87.76%-6K | --0 | --0 | --0 | ---6K | ---49K | ---18K | ---19K |
| Net common stock issuance | ---- | ---- | --0 | --0 | ---- | ---- | ---- | --608K | --0 | --0 |
| Proceeds from stock option exercised by employees | 34.62%35K | 239.29%190K | 0.68%149K | --57K | -28.57%10K | -78.33%26K | 300.00%56K | -97.83%148K | --0 | -99.70%14K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 34.62%35K | 280.00%190K | -79.77%143K | 416.67%57K | 300.00%10K | -75.93%26K | -91.96%50K | -89.62%707K | -101.82%-18K | -100.11%-5K |
| Net cash flow | ||||||||||
| Beginning cash position | -53.31%21.81M | -53.45%20.75M | -36.06%44.58M | -31.99%21.63M | -51.73%22.65M | -30.86%46.71M | -36.06%44.58M | 4.31%69.72M | -48.87%31.81M | -36.63%46.93M |
| Current changes in cash | 43.28%-13.68M | -62.84%751K | 5.61%-23.91M | -104.92%-631K | 92.45%-1.17M | -17.35%-24.12M | 198.30%2.02M | -995.65%-25.33M | 71.05%12.81M | -30.81%-15.53M |
| Effect of exchange rate changes | -501.67%-241K | 171.93%310K | -56.52%80K | -479.07%-249K | -62.10%155K | 176.92%60K | 209.62%114K | 234.55%184K | -265.38%-43K | 1,310.34%409K |
| End cash Position | -65.17%7.89M | -53.31%21.81M | -53.45%20.75M | -53.45%20.75M | -31.99%21.63M | -51.73%22.65M | -30.86%46.71M | -36.06%44.58M | -36.06%44.58M | -48.87%31.81M |
| Free cash flow | -129.37%-8.78M | -126.50%-8.39M | 58.23%-18.45M | -3.20%-6.1M | 28.59%-4.82M | 75.17%-3.83M | 76.98%-3.71M | 30.01%-44.17M | 59.11%-5.91M | 61.09%-6.75M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
